克拉霉素联合噻托溴胺治疗CO PD患者的疗效和肺功能变化的药理分析

摘要

AIM:To explore the clinical efficacy and the chan-ges of pulmonary function of clarithromycin combined with tiotro-pium bromide for treating chronic obstructive pulmonary disease (COPD).METHODS:78 COPD patients were randomly divid-ed into two groups averagely:the observation group and control group.The observation group was treated with clarithromycin and tiotropium bromide,the control group was treated with tiotropium bromide.The pulmonary function FEV1/FVC,Cpn-IgA,Cpn-IgG,Cpn-lgM and CRP were compared in the two groups before and after treatment.RESULTS:After treatment,the pulmonary ventilation function in the two groups improved significantly,and the observation group was more obvious than that in the control group (P<0.05 ).The positive rates of Cpn-IgA,Cpn-IgG and Cpn-IgM before and after treatment had no significant changes in the control group (P>0.05 ).The positive rate of Cpn-IgM de-creased significantly in the observation group (P<0.05 ).The CRP levels in the two groups decreased,and the observation group decreased more significantly than the control group (P<0.05).CONCLUSION:Clarithromycin combined with tiotropi-um bromide for treating COPD can enhance the synergic role of two drugs with better efficacy.It is worth widely applying in clin-ic.%目的：探讨克拉霉素联合噻托溴胺治疗慢性阻塞性肺病（COPD）患者的疗效和肺功能变化．方法：将78例COPD患者随机平均分为观察组和对照组，观察组采用克拉霉素和噻托溴胺联合治疗，对照组采用噻托溴胺治疗，比较两组患者在治疗前后肺功能FEV1／FVC、肺炎衣原体Cpn-IgA、Cpn-IgG、Cpn-IgM阳性率和C反应蛋白（CRP）含量．结果：两组患者治疗后的肺功能均有显著改善，FEV1／FVC显著增加，且治疗后观察组的FEV1／FVC显著高于对照组（P＜0．05）；对照组的Cpn-IgA、Cpn-IgG、Cpn-IgM阳性率治疗前后差异无统计学意义（P＞0．05），观察组仅Cpn-IgM阳性率治疗后显著下降（P＜0．05）；两组患者治疗后的 CRP 含量均显著下降（P ＜0．05），且治疗后观察组的CRP含量比对照组下降更为显著（P＜0．05）．结论：克拉霉素联合噻托溴胺治疗COPD，具有明显的协同作用，值得更广泛的临床应用．